Effect of antiplatelet and anticoagulant medication use on injury severity and mortality in patients with traumatic brain injury treated in the intensive care unit - Summary - MDSpire
Advertisement
Effect of antiplatelet and anticoagulant medication use on injury severity and mortality in patients with traumatic brain injury treated in the intensive care unit
To study the impact of antiplatelet and anticoagulant medication on the severity of traumatic brain injury (TBI) and 1-year mortality, as well as other relevant clinical outcomes, in ICU-treated patients.
Key Findings:
Age and preinjury anticoagulant medication are independent predictors of post-TBI mortality.
Antiplatelet medication is associated with a small to non-existent increase in mortality.
Warfarin use is linked to a sixfold increase in TBI mortality, while DOACs do not increase in-hospital mortality for mild TBI patients.
Antiplatelet and anticoagulant medications do not increase mortality in trauma patients without TBI.
Interpretation:
The study suggests that the type of anticoagulant medication significantly influences TBI outcomes, with warfarin posing a higher risk compared to DOACs, which may inform clinical decision-making.
Limitations:
Retrospective design may introduce bias.
Data on medication adherence and timing relative to injury were not assessed, which may limit the applicability of the findings.
Conclusion:
Antiplatelet and anticoagulant medications affect TBI severity and mortality, highlighting the need for careful management in TBI patients.
by Juho Vehviläinen, Jyri J. Virta, Markus B. Skrifvars, Matti Reinikainen, Stepani Bendel, Tero Ala-Kokko, Sanna Hoppu, Ruut Laitio, Jari Siironen, Rahul Raj
